Standardized plant extracts derived from biomass of in vitro cultures, methods for preparing the same, and their use.

Abstract

The present invention refers to a standardized plant extract derived from the biomass of an in vitro culture of Haberlea rhodopensis Friv. (HR), containing bioactive compounds and their primary and secondary metabolites, and containing, by weight, the following: 4.0-6.0 organic acids, 0.5-1.5 fatty acids, 8.0-12.0 amino acids, 0.5-1.0 sterols, 3.0-6.0 free phenols, 45-55 sugars, and 25.0-35.0 polyphenols, with 70%-96% of the major myconosides in the polyphenol fraction, constituting 18%-35% of the total extract; a composition containing the standardized extract and glycerol; and a method for preparing the standardized plant extract. The method of the present invention, with optimally selected steps, specific conditions, and parameters, such as temperature, duration, agitation, light, and growth factors, achieves both maximum volumetric productivity of the target substance and maximum volumetric productivity of myconoside, as well as stable productivity of plant in vitro cultures, and is a reliable, efficient, 24 / 7 continuous system for the production of NPs. The dependence on natural factors, limited availability, and protection of rare wild plant populations of HR are eliminated. The limitations imposed by seasonal and slow HR growth are also circumvented by developing a renewable, environmentally friendly method. The developed method provides an alternative, renewable, and sustainable source of plant material needed to obtain the target extract. The resulting standardized myconoside extract is particularly valuable for its protective effects on human health and can be successfully utilized for its pharmacological and cosmetic benefits and in functional foods.

Description

Detailed Description of the Invention

[0001] 〔Field of the Invention〕 The present invention relates to standardized plant extracts, specifically extracts derived from the biomass of in vitro cultures and methods for preparing such extracts, where the plant extracts contain beneficial bioactive compounds (BACs) and secondary metabolites and can be used for the preparation of agents for the pharmaceutical, cosmetic or food industries.

[0002] 〔Background of the Invention〕 Natural plants contain diverse BASs, and their origin, growth conditions, harvesting time, extraction techniques, etc. affect the quality of the products.

[0003] Cultivated medicinal plants have more advantages than wild plants. Their growth can be observed, they can be harvested at the most favorable time, and moreover, access to inappropriate plant species can be avoided.

[0004] Haberlea is a monotypic genus, and H. rhodopensis Friv. (Rhodopean Silivryak), or simply (HR) is its only member. This plant is a Tertiary relic and is endemic to central and southern Bulgaria, found in the Balkan and Rhodope mountains, as well as in the Rhodope mountains, Pangaeon mountain and Falakro mountain in northeastern Greece. For centuries, H. rhodopensis has been traditionally used in ethnopharmacology and local traditional medicine (1).

[0005] It is known that plant extracts have been isolated from HR leaves. The bio-compounds isolated from plant extracts are a source of essential natural components. Apart from fruits and vegetables, polyphenols, glycosides, sugars, etc. are also found in plants and play an important role in human health due to their physiological functions.

[0006] It is known that an ethanol extract of HR can be obtained by spray-drying the entire plant, extracting it with ethanol for 3 hours with stirring at room temperature, filtering to separate insoluble matter, then concentrating under reduced pressure and freeze-drying to obtain the extract. The same source also provides information on a water-soluble HR extract, in which the entire plant is spray-dryed and extracted in hot water at 120°C in an autoclave for 20 minutes, after which insoluble matter is separated by filtration at high temperature and freeze-dried. The resulting extract has anti-aging, antioxidant, skin whitening, and immunostimulatory effects (5).

[0007] There are reports of extracts of HR obtained by water-alcohol extraction (ethanol / water, unspecified preparation method) and purified by gel filtration chromatography on Sephadex LH-20, which contain an isolated fraction particularly rich in phenylethanoid glycosides, myconosides involved in the biological activity of Haberlea extract. In the same source, the efficacy of the extract was observed and reported that myconosides have cytoprotective and UV-protective effects, act as anti-aging agents for the skin, protect the skin from oxidation, increase its elasticity and enhance its radiance, and have potential cosmetic applications (3).

[0008] Furthermore, the phytochemical composition of a 70% ethanol extract of HR leaves contains a large group of major bioactive compounds, including secondary metabolites containing myconosides (phenolic acids, flavonoids, fatty acids, phytosterols, carotenoids, soluble lipids, oligosaccharides and polysaccharides, free sugars, polyols, organic acids, etc.), and is known to have proven antioxidant and hepatoprotective effects (1).

[0009] Data on the phytochemical aspects of methanol extracts of HR leaves containing two phenolic glycosides: myconoside and paucifloside, prepared using a combination of liquid-liquid extraction, preparative high-performance liquid chromatography, and semi-preparative high-performance liquid chromatography are also available. The myconoside-rich fraction (caffeoylphenylethanoid glycoside) has a potential role in plant survival and possesses antioxidant activity due to the presence of a caffeoyl group and two free hydroxyl groups in its phenyl ring. The major BACs and secondary metabolites found in various HR extracts during normal growth and drying periods of plant growth are organic acids, fatty acids, amino acids, phenolic acids, and sugars (4).

[0010] Today, HR extracts obtained directly from naturally growing species are successfully applied in cosmetics, homeopathy, and pharmacy due to their proven antibacterial, antiviral, antioxidant, immunomodulatory, cytotoxic, anticancer, chemopreventive, genoprotective, and radioprotective properties.

[0011] On the other hand, because it is a particularly valuable and rare endemic species, HR is included in the list of plant species whose collection from nature is prohibited. For example, in recent years, in vitro systems for the regeneration and mass propagation of HR have been established with the aim of protecting the natural population of this rare plant species. In vitro banks of HR plants from various locations have been set up. The same source also describes an effective method for regeneration and mass propagation in which the seeds of the plant species are sterilized with 70% EtOH for 1 minute, treated with hypochlorite for 6-10 minutes, treated with 0.1% HgCl2 for 3-5 minutes, rinsed three times with distilled water, and the resulting sterilized HR seeds are placed on classical hormone-free MS medium (MS B5, similar to WPM) and germinated for 3-4 months to obtain seedlings. By subculturing the plant clusters for 1-1.5 months, an in vitro system of fully developed plants was obtained and ready for transformation over a 6-7 month process under non-sterile conditions in a controlled greenhouse environment (2).

[0012] Simultaneously, plant biotechnology, specifically the in vitro culture of plant cells, has become a promising tool for the sustainable and continuous production of plant-derived BACs. The principles of plant cell culture and proliferation in solid and liquid nutrient media, as well as the general processes related to the establishment and culture of plant cells, have been described for plant species other than those of HR.

[0013] According to (6), separate extracts have been obtained from plant cell cultures of Rosa sp., containing valuable natural products (NPs) for cosmetic skin and hair care that prevent signs of aging. Plant cell biomass has been used for the production of phenylpropanoids from Ajuga repens, and verbascoside from Olea europea, Syringa vulgaris, or Appia citobara, as well as for the production of a standardized verbascoside extract from Syringa vulgaris cell cultures, which, according to (7), have proven antioxidant activity and are effective in treating acne and preventing hair loss.

[0014] According to (8), preparations in the form of in vitro culture extracts of Argania spinosa have also been made for the treatment of skin aging and skin inflammation.

[0015] According to (9), standardized extracts obtained from in vitro undifferentiated plant cells of Dracocephalum ruyschiana contain BAC, which has proven anti-radical activity and cosmetic applications for skin protection and regeneration, and are obtained by growing in semi-solid or liquid culture media, separating the cellular biomass in the dark or with a photoperiod of 14-16 hours, followed by biomass extraction with ethanol or ethanol, glycerol and water in a ratio of 20:20:60-50:50:0 (v / v), drying the biomass, and further extraction with the same extract.

[0016] To date, there have been no reports on biomass-derived extracts of HR in vitro cultures, including BAC and secondary metabolites.

[0017] Despite the fact that general principles for culturing plant cells are not applicable to large-scale cell proliferation for production purposes, it is necessary to develop specific technical processes. To maintain plant in vitro cultures (differentiated or undifferentiated) under in vitro culture conditions, it is crucial to determine the optimal and strictly specific ratios of growth regulators (auxins, cytokinins, and gibberellins) and establish them for each cell line (each plant species). Modifications of cell culture conditions, as well as the use of elicitors, precursors, and absorption matrices, are critical to the production of specific bioactive compounds / metabolites and are specific to the plant species used and the desired target compounds.

[0018] However, the synthesis of valuable BACs and metabolites in in vitro culture is a complex process with many unknown parameters. The accumulation of native components and secondary metabolites in cellular biomass is due to a dynamic balance between biosynthesis, biotransformation, and biodegradation. For each component unique to intact plants, it is crucial to select appropriate and optimal conditions (i.e., nutrient media and stimulants).

[0019] In many cases, natural products obtained from traditional extracts lack sufficient homogeneity, and the amount of targeted therapeutic components tends to vary seasonally and geographically compared to those obtained from in vitro cultures. Furthermore, working with standardized raw materials is essential for obtaining in vitro biomass extracts and for their incorporation into products for the cosmetic, pharmaceutical, or food industries.

[0020] The object of the present invention is to obtain a standardized extract having a guaranteed content of phenylethanoid glycosides (i.e., myconosides) with the invariant physicochemical properties and constituent elements of the associated BAC / components, obtained by a biotechnological method with the most efficient design, specifically an extract derived from HR in vitro cultures (seedlings, shoot cultures, root cultures (normal roots, adventitious roots and hairy roots), somatic cell embryos, callus cultures, cell suspension cultures).

[0021] [Summary of the Invention] The problems of the present invention are solved by biomass-derived extracts of HR in vitro cultures (seedlings, shoot cultures, root cultures (normal roots, adventitious roots and hairy roots), somatic cell embryos, callus cultures, cell suspension cultures) containing BAC, which includes secondary and primary plant metabolites (i.e., fatty acids, sterols, organic acids, amino acids, free phenolic acids, and sugars). The amount of BAC in the extract is, in weight percent: fatty acids 0.5-1.5, sterols 0.5-1.0, organic acids 4.0-6.0, amino acids 8.0-12.0, free phenols 3.0-6.0, sugars 45.0-55.0, and polyphenol compounds 25.0-35.0%, and contains phenylethanoid glycosides (i.e., myconosides) which account for 70-96% of the polyphenol fraction. Extracts obtained from the biomass of HR in vitro cultures are rich in myonosides and standardized, with myonoside content ranging from 18% to 35% of the total extract. Dissolution of the standardized extract in glycerol yields a product having a controlled myonoside content of 0.01 to 15.00% in its composition, depending on the needs of the relevant industry (i.e., pharmaceutical, food, or cosmetic).

[0022] The standardized extract derived from the in vitro culture described in the present invention is prepared by a method comprising the following essential steps: 1) Initiation of in vitro culture derived from HR: - Selection of explants from individual parts or organs of a plant, specifically from leaves, stems, hypocotyls, roots, seeds, anthers, ovaries, sepals, and seedlings. - Surface sterilization of selected explants by repeatedly washing with sterile distilled water for 1 to 240 minutes, treating with 40 to 85% ethanol for 10 to 190 seconds, then treating with a 2 to 10% disinfectant for 10 to 60 minutes with or without a surfactant, washing with sterile distilled water, and drying for 1 to 20 minutes; - Initiation of sterile explants on semi-solid or liquid media with or without growth regulators, and cultivation for 2–5 weeks at 18–32°C, with photoperiods of 8–16 hours each in darkness or light and dark, and at a medium pH of 5.0–6.2 to obtain 85–100% differentiated or undifferentiated in vitro cultures (seedlings, shoot cultures, root cultures, somatic embryos, callus cultures, cell suspension cultures). Transplantation of the obtained initiated in vitro cultures for independent growth onto semi-solid nutrient media with or without growth regulators, and with or without reducing agents and / or antioxidants. Culturing is carried out for 15–45 days at 18–32°C under the same photoperiod to select 5–30% of the total number of in vitro cultures produced that are morphologically stable and yield high in terms of myconoside accumulation. The selected in vitro strains are maintained by regular subculturing every 20–35 days on fresh semi-solid medium with or without growth regulators.

[0023] 2) Biomass production: - Transplantation of selected high-yielding strains in sterile liquid nutrient medium supplemented with carbon sources, growth regulators, and antioxidants to obtain in vitro strains or so-called inoculum adapted to 70-100% liquid culture conditions; - Inoculation of the obtained inoculum into liquid medium and cultivation for 1 to 6 weeks in a flask, bioreactor or temporary immersion system (with an immersion period of 1 to 30 minutes and an exposure period of 1 to 12 hours) at 18 to 32°C under the same photoperiod until the control content of myconosides in the biomass reaches 80 mg or more per gram of dry biomass; then stimulation of secondary metabolite production for 3 to 15 days by adding factors selected from among elicitors, supply of fresh nutrient medium, addition of precursors, introduction of a second phase in the culture system for recovery of secreted secondary metabolites, or a combination thereof, in order to obtain myconoside-enriched biomass (100 mg or more per gram of dry biomass); - Separation of myconoside-enriched biomass from the culture medium, and drying or freeze-drying at 20-80°C (yield of dried biomass is 10-15 g / L or more), and optionally drying or freeze-drying of the obtained culture medium by reduced-pressure evaporation at 30-70°C (yield of dried product is 15-30 g / L or more); 3) Preparation of HR biomass extract by in vitro culture: - The obtained dried biomass is optionally mixed and homogenized with a culture medium in a homogenizer; - The dry mixture is macerated in 30-80% ethanol for 16-72 hours at 18-45°C, with or without sonication; - The resulting mixture is filtered, the precipitate is separated, and the filtrate is collected and dried under reduced pressure at a temperature of 30-70°C to obtain a viscous concentrate (extract) containing 10-30% water and myconoside content (150 g / kg or more) in the extract; and - Dissolve the obtained standardized extract by adding glycerol and stir until completely homogenized. The resulting solution will have a controlled myconoside content of 0.01% to 15.00%, depending on the needs of the relevant industry (i.e., pharmaceutical, food, or cosmetic).

[0024] Suitable nutrient media are standard semi-solid and liquid modifications selected from MS (Murashige and Skoog), WP (McCown Woody Plant), LS (Linsmaier and Skoog), Gamborg B5, Heller, Nitsch, Schenk, and White, or modified macro-salt compositions, micro-salts and vitamins. For the needs of this method, carbon sources such as sucrose and / or glucose (1% - 9%), 0 - 5% activated carbon, reducing agents such as 2-mercaptoethanol and / or dithiothreitol at a concentration of 0 - 10 mg / L, antioxidants such as ascorbic acid and / or citric acid at a concentration of 0 - 10 mg / L, and gelling agents agar or gelrite at a concentration of 0.1% - 10% are added to further modify the medium.

[0025] The main growth regulators are selected from auxins (picloram and α-naphthaleneacetic acid), cytokinins (kinetin and 6-benzylaminopurine), and / or gibberellins at a concentration of 0 - 20 mg / L. Picloram and / or α-naphthaleneacetic acid can be used as auxins together with gibberellic acid 4+7 and / or gibberellic acid A3 and cytokinins (i.e., kinetin and / or 6-benzylaminopurine). Other possible auxins are indole-3-acetic acid, indole-3-butyric acid, dicamba, p-chlorophenoxyacetic acid and β-naphthoxyacetic acid), cytokinins: 2-iP, 4-CPPU, 6-benzylaminopurine riboside, dihydrozeatin, zeatin, meta-topolin and thidiazuron), and gibberellins: gibberellic acid.

[0026] The elicitors used are selected from the following: biological agents, such as polysaccharides or chitosan; or abiotic agents, such as methyl jasmonate, jasmonic acid, abscisic acid, or those with physical agents (osmotic agents, UV light); these act as signals to stimulate the secondary metabolism of plant cells when added at very low concentrations. Other strategies can also be applied, such as the supply of fresh nutrient medium, or the addition of precursors (amino acids and sugars), or the introduction of a second phase (activated carbon or absorbent resin) into the culture system to capture the secreted secondary metabolites.

[0027] The culture of differentiated and undifferentiated in vitro cultures of HR is carried out as follows.

[0028] - In bioreactors with mechanical (stirred tank) and pneumatic (bubble column) agitation for submerged culture under controlled conditions, and having a tightly maintained microenvironment optimal for in vitro culture growth; - In a temporary immersion system within a semi-automated sterilization system having controlled conditions and a tightly maintained microenvironment optimal for the growth of differentiated cultures under in vitro conditions. A short-term controlled contact between the plant material and the nutrient medium is provided over a controlled period with temporary air agitation of the liquid phase, gravity or mechanical movement. Systems such as PLANTFORM, PLANTIMA, RALM, RITA, SETIS, or their analogs are used; - In flasks on an orbital shaker at 80 - 150 rpm.

[0029] The obtained extract produced by the in vitro HR culture biomass contains the target bioactive compounds and is rich in up to 35% polyphenol compounds (consisting of 70 - 96% myconosides), up to 55% sugars, and up to 12% amino acids of the mixture, making this extract highly valuable.

[0030] The standardized content of phenylethanoid glycosides (i.e., myconosides) makes the extract particularly valuable due to its protective effects on human health, its successful use for its pharmaceutical and cosmetic effects, and its functional nutritional value. The antioxidant effects of myconosides make them suitable for use in cosmetics due to their anti-aging, anti-wrinkle, and anti-pigmentation properties.

[0031] The method developed to prepare extracts according to the present invention uses optimally selected steps, specific conditions, and parameters such as temperature, time, stirring, light, and growth factors to obtain not only the maximum volume productivity of target substances and myconosides, but also stable productivity of plant in vitro cultures, as well as a reliable and efficient 24 / 7 continuous system for NP production.

[0032] The dependence on natural factors, limited availability, and protection of HR rare wild plant populations will be eliminated. Limitations imposed by seasonal and slow HR growth will also be circumvented by developing renewable and environmentally friendly methods. These methods will provide alternative, renewable, and sustainable sources of raw materials necessary to obtain target extracts.

[0033] Batch uniformity of the final NP, as well as consistent quality and guaranteed quantities of myconosides in standardized extracts produced by HR in vitro cultures, are ensured.

[0034] In addition, the appropriate culture medium used, along with optimal levels of growth factors and added stimulants, leads to the successful formation of in vitro cultures (seedlings, shoot cultures, root cultures, somatic cell embryos, callus cultures, cell suspension cultures) and the generation of biomass containing beneficial BACs of the target. The resulting cultures have significant scale-up potential in industrially relevant bioreactors and transient immersion systems designed to maximize the yield and content of biosynthetic NPs.

[0035] The type and concentration of the stimulants used (elicitors, precursors, and absorption phases), as well as the age and stage of development of the in vitro culture at the time of extraction, are particularly important factors that, when using the method of the present invention, are optimized and contribute to higher levels of biosynthesis and accumulation of NPs, especially those with complex molecular structures.

[0036] The risk of microbial contamination is eliminated as well as contamination of the in vitro biomass and the resulting extract by biological material from other plant, fungi, microorganisms, or animal species. Therefore, extracts with diverse and valuable naturally occurring chemical compositions and contents of BAC, as well as the methods used to obtain maximum biomass yield and extract, are considered preferred and particularly suitable for standardization in phenylethanoid glycosides for implementation in the food, cosmetic, or pharmaceutical industries.

[0037] [Examples] The present invention will be described below in detail in the following examples, but this is not intended to limit the invention: (Example 1) 1) Initiation of in vitro culture of HR: 1.1 Washing Wash 10 to 50 HR seeds, 0.6 mm x 0.1 mm in size, twice in sterile distilled water with 0.5 mg / l of gibberellin for 30 to 60 minutes each, treat with 70% ethanol for 100 seconds and 8% calcium hypochlorite for 50 minutes, then wash twice in sterile distilled water for 5 to 10 minutes each, and dry the resulting sterile seeds on sterile filter paper for 10 to 15 minutes.

[0038] 1.2.Start Sterile seeds are evaluated for quality and morphology, dead and morphologically altered individuals are removed and transplanted into semi-solid standard MS nutrient medium (pH 6.0) containing 5% sucrose and 5% agar, pre-sterilized at 121°C for 30 minutes, for initiation. The seedlings are incubated in the dark for 2 weeks in a thermostat at 28°C ± 2°C, monitoring sterility until 95–100% of seedlings have emerged.

[0039] 1.3.Independent growth For independent growth, the obtained seedling in vitro cultures are transplanted onto semi-solid MS nutrient medium (pH 6.0) supplemented with 5% sucrose and 5% agar. The cultures are incubated in a thermostat at 28±2°C in light / dark mode for 12 hours, for 30–35 days, until morphologically stable strains are obtained. Myconozide-overproducing strains are selected by periodically measuring the amount of myconozide produced in the cultures and selecting 25% of the high-yielding strains from the total number of in vitro strains produced.

[0040] 2) Biomass production: 2.1. Maintenance and adaptation of selected in vitro seedlings - subculturing The selected strains are maintained by regularly subculturing them every 30 days on fresh semi-solid nutrient medium (same as in step 1.3), monitoring changes in morphology and stability, and analyzing the amount of myconosides. 10 g of biomass is taken from high-yielding strains and cultured in a 2000 ml flask on a 140 rpm orbital shaker in sterile liquid MS medium with the same additives and pH, while monitoring changes in morphology, growth, uniformity, stability, and myconoside levels. 95-100% of the most adaptable strains are then used as inoculants for the next liquid culture.

[0041] 2.2. Cultivation of in vitro seedling systems adapted for biomass production Inoculation is performed at 20 days of age (logarithmic growth phase) using a liquid culture of 25 g fresh weight / l. Culturing is carried out at 28°C for 12 hours in light / dark for 5 weeks in a temporary immersion system with a 25-minute immersion period and a 6-hour exposure period. As a result, 180 g of fresh biomass is obtained per liter, and the myconoside content is 105 mg per gram of dry biomass. 2.3. Promotion of Biomass Production Biomass from 20 to 40 days old (logarithmic growth phase) is sterile-added with abiotic elicitors jasmonic acid and methyl jasmonate at a concentration of 5 mg / l, and cultured for 12 days under the above conditions. At the end of the process, concentrated biomass with a myonoside content of 152 mg per gram of dry biomass is obtained. After separating the biomass from the culture medium by filtration through a sterile sieve, it is washed with sterile distilled water and dried in a ventilated drying oven at 60°C. The yield is 15 g of dry biomass per liter. The quality of the biomass obtained in each batch is monitored for myonoside content and phenolic compounds.

[0042] The culture medium is collected and dried in a vacuum evaporator at 60°C. The yield is 30 g / l dry weight.

[0043] Fig. 1 shows comparative HPLC profiles of myconoside content from biomass derived from HR in vitro cultures (A), wild plant biomass (B), and extracts from biomass derived from HR in vitro seedling cultures (C).

[0044] 3) Preparation of myconoside-standardized extracts from biomass of in vitro HR seedling cultures: The obtained dried biomass and culture medium were mixed and homogenized in a homogenizer. For this purpose, 2 kg of dried biomass and 2.5 kg of dried culture medium (obtained from 200 L of in vitro seedling culture grown under liquid conditions) were used. A water-ethanol mixture of 70% ethanol was added in a hydromodule 20 (weight / volume) at 40°C for 35 hours, with sonication every 4 hours for 15 minutes. The resulting precipitate was removed by vacuum filtration, the filtrate was collected, and dried by vacuum evaporation at 40°C to obtain a viscous concentrate containing 12% water.

[0045] A biomass extract is obtained from a 1 kg HR in vitro seedling culture containing 208 g / kg of myconoside.

[0046] The extracts were phytochemically characterized, and the results are shown in Table 1. The amount of myconosides, as well as the content of phenolic compounds, fatty acids, organic acids, amino acids, sugars, and sterols, were monitored by HPLC and GC / MS.

[0047] The HPLC content of myconosides in extracts derived from HR in vitro biomass obtained according to Example 1 is shown in Table 2, compared to standard 70% ethanol extracts derived from HR plants growing in their natural habitats and standard 70% ethanol extracts derived from HR in vitro seedling cultures.

[0048] 3.1. Dissolution of myconosides in HR in vitro culture extracts 240.4 g of extract containing 208 g / kg of myconoside is mixed with 759.6 g of glycerol to produce 1 kg of extract containing 5% myconoside. The resulting mixture is stirred using a vibrating stirrer until the extract is completely homogenized. The resulting solution is packaged in sterile packs and stored for use in cosmetics, pharmaceuticals, or dietary supplements. For cosmetic purposes, standardized extracts derived from HR in vitro cultures are suitable in amounts of 0.1-15% for products such as creams, emulsions, and gels. Table 3 also shows a comparative analysis of the antioxidant properties of the extracts derived from HR in vitro cultures obtained according to Example 1 compared with a standard 70% ethanol extract derived from wild-growing HR plants. The ability of the extracts to capture free DPPH and ABTS radicals, as well as their ability to reduce copper(II) and iron(III) ions, was evaluated.

[0049] [Table 1]

[0050] An Agilent Technology Hewlett Packard 7890 A + / MSD 5975 instrument (Hewlett Packard, Palo Alto, CA, US) was used in combination with an Agilent Technology 5975C inert XL EI / CI MSD mass spectrometer (Hewlett Packard, Palo Alto, CA, US). An HP-5MS column (30 m × 250 μm × 0.25 μm) was used, with a temperature program of 60°C for 2 minutes (with a temperature increase of 5°C / min to 260°C), followed by exposure at 260°C for 8 minutes. The volume of injected sample was 1 μl with a 10:1 splitting ratio. The injector temperature was 250°C (using a flow transport gas (helium) of 1 mL / min). The EI / MS spectrum was recorded at 70 eV.

[0051] The HPLC system, Waters 1525 binary pump (Waters, Milford, MA, USA), and Waters 2487 Dual λ absorbance detector (Waters, Milford, MA, USA) were operated with Breeze 3.30 software; Supelco Discovery HS C18 column (5 μm, 25 cm × 4.6 mm), t 28°C; mobile phase with gradients of 2% acetate and acetonitrile;

[0052] [Table 2]

[0053] (Example 2) This method is the same as in Example 1, except that the leaves of HR are treated instead of seeds, and the root culture is prepared and used as an in vitro culture. The culture is carried out in a bubble column, biosynthesis is enhanced by supply instead of induction, and the resulting extract contains only accumulated biomass without the culture medium.

[0054] 1) Initiation of in vitro culture from HR: 1.1. Cleaning Wash 3 to 10 young HR leaves, 2 to 5 cm in size, in sterile distilled water with detergent (Tween 80) for 3 minutes, treat with 80% ethanol for 60 seconds and 6% calcium hypochlorite for 30 minutes, wash three times with sterile distilled water for 3 minutes each, and dry on sterile filter paper for 2 minutes.

[0055] 1.2.Start Sterile leaves are treated by excising dead areas. The leaves are then cut into 0.5–1.0 cm sections and started on semi-solid standard B5 nutrient medium supplemented with 4% sucrose and 8 mg / l picoram, 3% gellite, pre-sterilized at 121°C for 30 minutes, with additional supplementation of 5 mg / l ascorbic acid and 5 mg / l 2-mercaptoethanol, pH 5.5. Culture is carried out in the dark at 24°C ± 2°C for 4 weeks, monitoring sterility until root cultures are formed from the leaves in 90% of the explants.

[0056] 1.3.Independent growth The obtained adventitious root in vitro cultures were individually cultured in a thermostat at 24°C in the dark for 37 days on a medium containing 3 g / l of activated carbon, the same medium as in step 1.2 of Example 2, to obtain morphologically stable myconoside-overproducing strains. From the total number of in vitro strains produced, 15% of high-yielding strains were selected.

[0057] 2) Biomass production 2.1. Maintenance and adaptation of selected in vitro root cultures - subculturing The selected root cultures are maintained by regularly subculturing them every 37 days on the semi-solid fresh medium as in step 1.3 of Example 2, monitoring changes in morphology and stability, and determining the amount of myconoside. 15 g of biomass from high-yielding strains is cultured in a 500 ml flask on a 100 rpm orbital shaker in sterile liquid B5 medium with the same additives as in step 1.3 of Example 2, and 85% of the most adaptable strains are used as inoculants for the next liquid culture.

[0058] 2.2 Cultivation of in vitro root cultures adapted for biomass production A 30-day-old root culture in the logarithmic growth phase with a fresh weight of 30 g / l is cultured for 4 weeks at 24°C ± 2 in the dark in a bubble column with an air flow rate of 0.3 l / l / min in the same amount of liquid B5 medium as in step 1.3. 130 g / l of fresh biomass yields dry biomass with a myconoside content of 120 mg / g.

[0059] 2.3. Promotion of Biomass Production The biomass in the late logarithmic growth phase (35 days old) is sterile-replenished with fresh liquid B5 medium up to the maximum operating volume of the bioreactor and cultured for 10-15 days under the conditions described above. The result at the end of the process is concentrated biomass containing 170 mg of myconoside per gram of dry biomass. The obtained biomass is separated from the culture medium by filtration, washed, and dried. The yield is 12 g of dry biomass per liter.

[0060] 3) Preparation of myconoside-standardized extracts from in vitro biomass of HR root cultures: Three kilograms of dried biomass derived from in vitro cultured roots was pulverized and subjected to extraction by maceration with an 80% ethanol aqueous solution in Hydromodule 40 (weight / volume) for the same time and temperature as in Example 1, except that sonication was not performed, to obtain a viscous concentrate containing 5% water. A 500 g biomass extract derived from in vitro HR root cultures containing 280 mg / g of myconoside was obtained.

[0061] 3.1. Dissolution of the obtained HR in vitro root culture extract regarding myconoside content Weigh 357.1 g of myconoside-rich HR in vitro root culture into a container. Add 642.9 g of glycerol to the desired weight of 1 kg of extract containing 10% myconoside. Stir the resulting mixture until the extract is completely homogenized by sonication, then package in sterile packs and store for future use.

[0062] (Example 3) The procedure was carried out as in Example 1, except that the ovary was processed instead of the seed, and callus and cell suspension cultures were obtained instead of seedling cultures and used as in vitro cultures. The culture was performed in an Erlenmeyer flask.

[0063] 1) Initiation of in vitro callus culture from HR 1.1. Cleaning Two to five newly formed HR ovaries, each 0.2 to 0.5 cm in size, are washed in sterile distilled water for 1 to 2 minutes, treated with 70% ethanol for 90 seconds and 10% sodium hypochlorite for 40 minutes, then washed with sterile distilled water for 1 minute and dried on sterile filter paper for 1 minute.

[0064] 1.2.Start The obtained sterile ovaries are horizontally cut in half and transplanted onto standard WP nutrient medium (pH 5) supplemented with 2% sucrose, 1 mg / l 1-naphthaleneacetic acid, 1 mg / l 6-benzylaminopurine, and 4% agar, pre-sterilized at 121°C for 30 minutes, and cultured at 26°C ± 2°C in the dark for 3 weeks, monitoring the sterile condition until callus formation occurs in 93% of the explants.

[0065] 1.3.Independent growth The obtained in vitro callus cultures are prepared for 27 days of independent growth in a thermostat at the same temperature and in the dark on medium supplemented with 3 mg / l citrate and 1 g / l activated carbon, the same medium as in step 1.2, in order to obtain morphologically stable myconoside-overproducing strains. Here, 11% of the high-yielding strains are selected from the total number of in vitro strains produced.

[0066] 2. Biomass Production 2.1. Maintenance, adaptation, and formation of cell suspension cultures of selected in vitro cultures. The selected callus cultures are maintained by regularly subculturing them every 27 days on fresh semi-solid WP nutrient medium from the previous step, monitoring changes in morphology and stability, and analyzing the amount of myconoside. The same amount of biomass from high-yielding strains as in step 2.2 of Example 2 is cultured in a 1000 ml flask on an 80 rpm orbital shaker in sterile liquid WP medium with the same additives as in the previous step to obtain cell suspension cultures consisting of small and medium-sized aggregates, and 75% of the most adaptable strains are continued as inoculants for the next liquid culture.

[0067] 2.2. Culturing of cell suspension cultures adapted for biomass production A 7-day-old cell suspension culture in the logarithmic growth phase with a fresh weight of 100 g / l is cultured in a 2000 ml flask on an 80 rpm orbital shaker at 26°C in the dark for 9 days. The resulting biomass yields 110 g / l of fresh biomass with a myconoside content of 80 mg per gram of dry biomass.

[0068] 2.3. Promotion of Biomass Production At the late logarithmic growth stage (6 days old), 1 g of sterile absorbable resin (Amberlite XAD7) is sterile-added to the biomass as a second phase. The culture is continued for a further 4 days to obtain concentrated biomass with a myonoside content of 100 mg per g of dry biomass. This is then processed as in Example 1, and the biomass and culture solution are freeze-dried at -40°C. The yield is 9 g of dry biomass and 15 g of dry weight culture solution per liter.

[0069] 3) Preparation of myconoside-standardized extracts from in vitro biomass of HR suspension cultures The entire contents of 1 kg of dried biomass and culture medium were homogenized, and, as in Example 1, extracted by maceration with a water-ethanol mixture of 30% ethanol at the same temperature and duration, with precipitation, separation, and drying, to obtain a viscous concentrate containing 20% ​​water.

[0070] Obtain 100 g of biomass-derived extract from an in vitro cell suspension culture of Haberlea rhodopensis containing 150 mg / g of myconoside.

[0071] 3.1. Dissolution of the obtained in vitro HR suspension culture extract regarding myconoside content Weigh 100.0 g of myconoside-rich HR extract obtained from in vitro cell suspension culture. Add 400.0 g of glycerol to the desired weight of 500 g of extract containing 3% myconoside. Stir the mixture using a rotary or high-pressure homogenizer until the extract is completely homogenized, then pack the resulting solution into a sterile container and store for future use.

[0072] [Table 3]

[0073] DPPH (2,2-diphenyl-1-picrylhydrazyl) / HR extract / 0.1 mM solution of DPPH radical / 15 minutes in the dark at 21°C / decrease in absorbance at λ=517 nm compared to control sample (methanol added) / EC 50 Determination of the effective concentration (that inhibits DPPH radicals by 50% in a 0.1 mM DPPH solution).

[0074] Results as Trolox ((±)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) were obtained by adding TEAC / ABTS(2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) radical / HR extract to a pre-prepared solution of ABTS radicals / in the dark at 21°C for 15 minutes / compared to the absorbance of the control (with methanol added), with a decrease of % / mM in absorbance at λ=734 nm.

[0075] To evaluate the reducing ability, use the following: CUPRAC / HR extract / solution of Cu(II) ions in the presence of the chelating agent neocuproine / reduction from Cu(II) to Cu(I) in the dark at 21°C for 15 minutes / absence maximum at λ=450nm / mM Trolox results; FRAP-HR extract / Fe(III) ion solution in the presence of TPTZ (2,4,6-tris(2-pyridyl)-s-triazine) / 15 minutes in the dark at 21°C / Reduction from Fe(III) to Fe(II) / Fe-TPTZ complex / Absorption maximum at λ=593nm / mM Trolox results

[0076] [Table 4]

[0077] References: (1) Journal of Ethnopharmacology “The ancient Thracian endemic plant Haberlea rhodopensis Friv. And related species: A rewiew“, 2019, Yordan N. Georgiev; (2) Plant Cell, Tissue and Organ Culture (2005) 80: 115-118 Djilianov, (3) International Journal of Cosmetic Science, 2012, 34, 132-139 “Skin benefits of a myconoside-rich extract from resurrection plant Haberlea rhodopensis”, Dell Acqua and Schweiker; (4) Natural Product Research: Formerly; Natural Product Letters“Haberlea rhodopensis: pharmaceutical and medical potential as a food additive“, 2015; Rumiana Todorova; (5) JP2011168560A; (6) JP2015503212 ; (7) EP 1736167; (8) RU 2 559579; (9) WO2019175829。

Claims

1. A myonoside-standardized plant extract containing bioactive compounds and their primary and secondary metabolites, wherein the bioactive compounds and their primary and secondary metabolites are organic acids, sterols, free phenolic acids, sugars, and polyphenols. The myonoside standardized plant extract is produced from in vitro cultured biomass of Haberlea rhodopensis Friv (HR) and contains, by weight %, the following: 4.0–6.0 organic acids, 0.5–1.5 fatty acids, 8.0–12.0 amino acids, 0.5–1.0 sterols, 0.47 free phenolic acids, 45–55 sugars, and 25.0–35.0 polyphenols. The aforementioned polyphenol fraction contains 70% to 96% of the main myonosides, constituting 18% to 35% of the total extract. The myonoside-standardized plant extract is characterized by being a plant extract derived from in vitro cultured biomass of HR, standardized by myonoside content.

2. A composition containing the myconoside standardized plant extract described in claim 1, A composition characterized by also containing glycerol and having a myonoside content of 0.01% to 15.00%.

3. A method for preparing a myconoside standardized plant extract according to claim 1 by in vitro culture, The HR explants are repeatedly washed with sterile distilled water for 1 to 240 minutes, treated with 40 to 85% ethanol for 10 to 190 seconds, then treated with 2 to 10% disinfectant for 10 to 60 minutes with or without surfactant, repeatedly washed with sterile distilled water, and dried for 1 to 20 minutes. The obtained sterile explants are cultured for 2 to 5 weeks on a semi-solid or liquid sterile nutrient medium with or without growth regulators at 18 to 32°C, in the dark or with an 8 to 16-hour light-dark period, at a pH of 5 to 6.2, to obtain cultures that are 85 to 100% differentiated or undifferentiated. Next, the in vitro cultures were grown independently for 15 to 45 days at 18 to 32°C on semi-solid sterile nutrient medium with or without growth regulators, and with or without reducing agents and / or antioxidants, in the same photoperiod as the aforementioned dark or 8 to 16-hour light-dark cycle, to obtain in vitro cultures that overproduced 5 to 30% of the total number of generated in vitro strains and were morphologically stable. These were then maintained for 20 to 35 days on fresh semi-solid medium with or without growth regulators. The obtained high-yielding in vitro cultures are cultured in sterile liquid nutrient medium supplemented with a carbon source, growth regulators, and / or antioxidants to obtain 70-100% cell lines adapted to liquid culture, i.e., inoculants. These inoculants are then re-inoculated into the sterile liquid nutrient medium for further culture at 18-32°C, with the same photoperiod as the aforementioned dark or 8-16 hour light-dark photoperiod, for 1-6 weeks, until a control myconoside content of 80 mg or more per gram of dry biomass is obtained in the biomass. This is done in a temporary immersion system having an immersion period of 1-30 minutes and an exposure period of 1-12 hours, at the same photoperiod as the aforementioned dark or light-dark photoperiod. The high-yielding in vitro cultures are in vitro cultures that overproduce the selected myconoside and are morphologically stable, and are maintained for 20-35 days on fresh semi-solid medium with or without growth regulators. Next, over a period of 3 to 15 days, factors that enhance the biosynthesis of plant secondary metabolites are added, selected from elicitors, fresh nutrient medium supplementation, precursor addition, inclusion of a second phase in the culture system, or a combination thereof, to obtain myconoside-enriched biomass. Next, the obtained biomass is separated from the culture medium and dried or freeze-dried at 20-80°C to obtain a yield of 10-15 G / L or more of dry biomass. The obtained culture medium is evaporated or freeze-dried at 30-70°C to obtain a yield of 15-30 G / L or more of dry mass. The resulting dry mixture is then homogenized in a homogenizer and macerated with 30-80% ethanol at 18-45°C for 16-72 hours, with or without sonication. The dried mixture obtained above is filtered, the precipitate is separated, the resulting filtrate is collected and concentrated under reduced pressure at 30-70°C to obtain a viscous concentrate (extract) containing myconoside and having 10-30% water. A method for preparing a myconoside-standardized plant extract, characterized by finally dissolving the obtained viscous concentrate by adding glycerol and homogenizing it until completely dissolved to obtain a myconoside-standardized plant extract derived from an in vitro culture of Haberlea rhodopensis Friv.

4. The method for preparing a myconoside-standardized plant extract according to claim 3, characterized in that the HR explants to be washed and sterilized are selected from leaves, stems, hypocotyls, roots, seeds, anthers, fruit ovaries, sepals, and seedlings.

5. The method for preparing a myconoside-standardized plant extract according to claim 3, characterized in that the differentiated or undifferentiated culture of the sterile explant obtained at the start is selected from seedlings, meristematic tissue cultures, root cultures (normal roots, adventitious roots and hairy roots), somatic cell embryos, callus cultures, and cell suspension cultures.

6. Myconoside-enriched biomass produced from differentiated and undifferentiated in vitro cultures of Haberlea rhodopensis Friv according to claim 3, The biomass is characterized by containing myconosides.

7. Use of myconoside-enriched biomass according to claim 6 for the preparation of myconoside-standardized plant extracts containing myconosides.

8. Use of myconoside standardized plant extracts according to any one of claims 1 to 3 and 7 for the preparation of products intended for use in the food, cosmetic, or pharmaceutical industries.

Images